The study found that although PG alone had strong immunomodulatory and tumor-suppressive effects, raising tumor growth inhibition (TGI) to 57% at day 18 (compared to 36% with anti-PD-L1 antibodies), combination treatment did not show any appreciable improvement in survival time or reduction in tumor size. The gene discussed is CD274; the disease is neoplasm.